The role of serial cardiac biomarkers in prognostication and risk prediction of chronic heart failure: additional scientific insights with hemodynamic feedback

References

• Savarese G, Becher PM, Lund LH, et al. Global burden of heart failure: a comprehensive and updated review of epidemiology. Cardiovascular Research. 2022 Feb; p. 12.
   Google Scholar
• Ziaeian B, Fonarow GC. Epidemiology and aetiology of heart failure. Nat Rev Cardiol. 2016 Jun;13(6):368–378.
   PubMed Web of Science ®Google Scholar
• Cook C, Cole G, Asaria P, et al. The annual global economic burden of heart failure. Int J Cardiol. 2014 Feb 15;171(3):368–376.
   PubMed Web of Science ®Google Scholar
• Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: executive Summary: a Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2022 May 3;145(18):E876–E894.
   Google Scholar
• Fonarow GC, Stevenson LW, Peacock WF, et al. Admission B-type natriuretic peptide levels in acute decompensated heart failure predict in-hospital mortality: an analysis of 48,629 hospitalizations in ADHERE. J Card Fail. 2005 Aug;11(6):S167–S167.
   Web of Science ®Google Scholar
• Doust JA, Pietrzak E, Dobson A, et al. How well does B-type natriuretic peptide predict death and cardiac events in patients with heart failure: systematic review. Br Med J. 2005 Mar 19;330(7492):625–627.
   PubMed Web of Science ®Google Scholar
• Masson S, Latini R, Anand IS, et al. Direct comparison of B-Type natriuretic peptide (BNP) and amino-terminal proBNP in a large population of patients with chronic and symptomatic heart failure: the valsartan heart failure (Val-HeFT) data. Clin Chem. 2006 Aug;52(8):1528–1538.
   PubMed Web of Science ®Google Scholar
• Wang TJ, Larson MG, Levy D, et al. Plasma natriuretic peptide levels and the risk of cardiovascular events and death. New Engl J Med. 2004 Feb 12;350(7):655–663.
   PubMed Web of Science ®Google Scholar
• Aimo A, Januzzi JL Jr., Vergaro G, et al. Prognostic Value of High-Sensitivity Troponin T in Chronic Heart Failure: an Individual Patient Data Meta-Analysis. Circulation. 2018 Jan 16;137(3):286–297.
   PubMed Web of Science ®Google Scholar
• Aimo A, Vergaro G, Passino C, et al. Prognostic Value of Soluble Suppression of Tumorigenicity-2 in Chronic Heart Failure: a Meta-Analysis. JACC Heart Fail. 2017 Apr;5(4):280–286.
   PubMed Web of Science ®Google Scholar
• Kempf T, von Haehling S, Peter T, et al. Prognostic utility of growth differentiation factor-15 in patients with chronic heart failure. J Am Coll Cardiol. 2007 Sep 11;50(11):1054–1060.
   PubMed Web of Science ®Google Scholar
• French B, Wang L, Ky B, et al. Prognostic Value of Galectin-3 for Adverse Outcomes in Chronic Heart Failure. J Card Fail. 2016 Apr;22(4):256–262.
   PubMed Web of Science ®Google Scholar
• Imran TF, Shin HJ, Mathenge N, et al. Meta-Analysis of the Usefulness of Plasma Galectin-3 to Predict the Risk of Mortality in Patients With Heart Failure and in the General Population. Am J Cardiol. 2017 Jan 1;119(1):57–64.
   PubMed Web of Science ®Google Scholar
• Stevenson LW, Zile M, Bennett TD, et al. Chronic ambulatory intracardiac pressures and future heart failure events. Circ Heart Fail. 2010 Sep;3(5):580–587.
   PubMed Web of Science ®Google Scholar
• Brugts JJ, Radhoe SP, Aydin D, et al. Clinical Update of the Latest Evidence for CardioMEMS Pulmonary Artery Pressure Monitoring in Patients with Chronic Heart Failure: a Promising System for Remote Heart Failure Care. Sensors (Basel), Vol. 21. 2021. p. 7.
   Google Scholar
• Metra M, Cotter G, Gheorghiade M, et al. The role of the kidney in heart failure. Eur Heart J. 2012 Sep;33(17):2135–+.
   PubMed Web of Science ®Google Scholar
• Mele D, Nardozza M, Ferrari R. Left ventricular ejection fraction and heart failure: an indissoluble marriage? Eur J Heart Fail. 2018 Mar;20(3):427–430.
   PubMed Web of Science ®Google Scholar
• Hartupee J, Mann DL. Neurohormonal activation in heart failure with reduced ejection fraction. Nat Rev Cardiol. 2017 Jan;14(1):30–38.
   PubMed Web of Science ®Google Scholar
• Volpe M, Carnovali M, Mastromarino V. The natriuretic peptides system in the pathophysiology of heart failure: from molecular basis to treatment. Clin Sci. 2016 Jan 1;130(2):57–77.
   Web of Science ®Google Scholar
• Metra M, Teerlink JR. Heart failure. Lancet. 2017 Oct 28;390(10106):1981–1995.
   PubMed Web of Science ®Google Scholar
• Francis GS, Benedict C, Johnstone DE, et al. Comparison of Neuroendocrine Activation in Patients with Left-Ventricular Dysfunction with and without Congestive-Heart-Failure - a Substudy of the Studies of Left-Ventricular Dysfunction (Solvd). Circulation. 1990 Nov;82(5):1724–1729.
   PubMed Web of Science ®Google Scholar
• Gardner RS, Ozalp F, Murday AJ, et al. N-terminal pro-brain natriuretic peptide - A new gold standard in predicting mortality in patients with advanced heart failure. Eur Heart J. 2003 Oct;24(19):1735–1743.
   PubMed Web of Science ®Google Scholar
• Hartmann F, Packer M, Coats AJS, et al. NT-proBNP in severe chronic heart failure: rationale, design and preliminary results of the COPERNICUS NT-proBNP substudy. Eur J Heart Fail. 2004 Mar 15;6(3):343–350.
   PubMed Web of Science ®Google Scholar
• Groenning BA, Raymond I, Hildebrandt PR, et al. Diagnostic and prognostic evaluation of left ventricular systolic heart failure by plasma N-terminal pro-brain natriuretic peptide concentrations in a large sample of the general population. Heart. 2004 Mar 1;90(3):297–303.
   PubMed Web of Science ®Google Scholar
• Savarese G, Musella F, D’Amore C, et al. Changes of Natriuretic Peptides Predict Hospital Admissions in Patients With Chronic Heart Failure A Meta-Analysis. Jacc-Heart Fail. 2014 Apr;2(2):148–158
   PubMed Web of Science ®Google Scholar
• Bettencourt P, Azevedo A, Pimenta J, et al. N-terminal-pro-brain natriuretic peptide predicts outcome after hospital discharge in heart failure patients. Circulation. 2004 Oct 12;110(15):2168–2174.
   PubMed Web of Science ®Google Scholar
• Mohebi R, Murphy S, Jackson L, et al. Biomarker prognostication across Universal Definition of Heart Failure stages. ESC Heart Fail. 2022 Dec;9(6):3876–3887.
   PubMed Web of Science ®Google Scholar
• Bracun V, van Essen B, Voors AA, et al. Insulin-like growth factor binding protein 7 (IGFBP7), a link between heart failure and senescence. Esc Heart Failure. 2022 Sep; p. 11.
   Google Scholar
• Piatek K, Feuerstein A, Zach V, et al. Nitric oxide metabolites: associations with cardiovascular biomarkers and clinical parameters in patients with HFpEF. ESC Heart Fail. 2022 Dec;9(6):3961–3972.
   PubMed Web of Science ®Google Scholar
• Konev AA, Kharitonov AV, Rozov FN, et al. CT-IGFBP-4 as a novel prognostic biomarker in acute heart failure. ESC Heart Fail. 2020 Apr;7(2):434–444.
   PubMed Web of Science ®Google Scholar
• Zile MR, Claggett BL, Prescott MF, et al. Prognostic Implications of Changes in N-Terminal Pro-B-Type Natriuretic Peptide in Patients With Heart Failure. J Am Coll Cardiol. 2016 Dec 6;68(22):2425–2436.
   PubMed Web of Science ®Google Scholar
• Anand IS, Fisher LD, Chiang YT, et al. Changes in brain natriuretic peptide and norepinephrine over time and mortality and morbidity in the Valsartan Heart Failure Trial (Val-HeFT). Circulation. 2003 Mar 11;107(9):1278–1283.
   PubMed Web of Science ®Google Scholar
• Berger R, Huelsman M, Strecker K, et al. B-type natriuretic peptide predicts sudden death in patients with chronic heart failure. Circulation. 2002 May 21;105(20):2392–2397.
   PubMed Web of Science ®Google Scholar
• Seronde MF, Gayat E, Logeart D, et al. Comparison of the diagnostic and prognostic values of B-type and atrial-type natriuretic peptides in acute heart failure. Int J Cardiol. 2013 Oct 9;168(4):3404–3411.
   PubMed Web of Science ®Google Scholar
• von Haehling S, Jankowska EA, Morgenthaler NG, et al. Comparison of midregional pro-atrial natriuretic peptide with N-terminal pro-B-type natriuretic peptide in predicting survival in patients with chronic heart failure. J Am Coll Cardiol. 2007 Nov 13;50(20):1973–1980.
   PubMed Web of Science ®Google Scholar
• Moertl D, Berger R, Struck J, et al. Comparison of Midregional Pro-Atrial and B-Type Natriuretic Peptides in Chronic Heart Failure Influencing Factors, Detection of Left Ventricular Systolic Dysfunction, and Prediction of Death. J Am Coll Cardiol. 2009 May 12;53(19):1783–1790.
   PubMed Web of Science ®Google Scholar
• von Haehling S, Filippatos GS, Papassotiriou J, et al. Mid-regional pro-adrenomedullin as a novel predictor of mortality in patients with chronic heart failure. Eur J Heart Fail. 2010 May;12(5):484–491.
   PubMed Web of Science ®Google Scholar
• Adlbrecht C, Hulsmann M, Strunk G, et al. Prognostic value of plasma midregional pro-adrenomedullin and C-terminal-pro-endothelin-1 in chronic heart failure outpatients. Eur J Heart Fail. 2009 Apr;11(4):361–366.
   PubMed Web of Science ®Google Scholar
• Feng ZK, Akinrimisi OP, Gornbein JA, et al. Combination Biomarkers for Risk Stratification in Patients With Chronic Heart Failure Biomarkers Prognostication in HF. J Card Fail. 2021 Dec;27(12):1321–1327.
   PubMed Web of Science ®Google Scholar
• Peet C, Ivetic A, Bromage DI, et al. Cardiac monocytes and macrophages after myocardial infarction. Cardiovasc Res. 2020 May 1;116(6):1101–1112.
   PubMed Web of Science ®Google Scholar
• Chapman AR, Adamson PD, Mills NL. Assessment and classification of patients with myocardial injury and infarction in clinical practice. Heart. 2017 Jan;103(1):10–18.
   PubMed Web of Science ®Google Scholar
• Bel MS, Soldevila JG, Llanos JO. Biological markers of myocardial necrosis. Rev Esp Cardiol. 2003 Jul;56(7):703–720.
   PubMed Web of Science ®Google Scholar
• McEvoy JW, Chen Y, Ndumele CE, et al. Six-Year Change in High-Sensitivity Cardiac Troponin T and Risk of Subsequent Coronary Heart Disease, Heart Failure, and Death. JAMA Cardiol. 2016 Aug 1;1(5):519–528.
   PubMed Web of Science ®Google Scholar
• Gravning J, Askevold ET, Nymo SH, et al. Prognostic effect of high-sensitive troponin T assessment in elderly patients with chronic heart failure: results from the Corona trial. Circ Heart Fail. 2014 Jan;7(1):96–103.
   PubMed Web of Science ®Google Scholar
• Myhre PL, O’Meara E, Claggett BL, et al. Cardiac Troponin I and Risk of Cardiac Events in Patients With Heart Failure and Preserved Ejection Fraction. Circ Heart Fail. 2018;Nov;11(11):e005312.
   PubMed Web of Science ®Google Scholar
• Yan I, Borschel CS, Neumann JT, et al. High-Sensitivity Cardiac Troponin I Levels and Prediction of Heart Failure: results From the BiomarCaRE Consortium. JACC Heart Fail. 2020 May;8(5):401–411.
   PubMed Web of Science ®Google Scholar
• deFilippi CR, de Lemos JA, Christenson RH, et al. Association of Serial Measures of Cardiac Troponin T Using a Sensitive Assay With Incident Heart Failure and Cardiovascular Mortality in Older Adults. Jama-J Am Med Assoc. 2010 Dec 8;304(22):2494–2502.
   PubMed Web of Science ®Google Scholar
• Cohn JN, Ferrari R, Sharpe N, et al. Cardiac remodeling-concepts and clinical implications: a consensus paper from an international forum on cardiac remodeling. J Am Coll Cardiol. 2000 Mar 1;35(3):569–582.
   PubMed Web of Science ®Google Scholar
• Burchfield JS, Xie M, Hill JA. Pathological Ventricular Remodeling: mechanisms: part 1 of 2. Circulation. 2013 Jul 23;128(4):388–400.
   PubMed Web of Science ®Google Scholar
• Mueller T, Jaffe AS. Soluble ST2–analytical considerations. Am J Cardiol. 2015 Apr 2;115(7 Suppl):8B–21B.
   PubMed Web of Science ®Google Scholar
• Emdin M, Aimo A, Vergaro G, et al. sST2 Predicts Outcome in Chronic Heart Failure Beyond NT-proBNP and High-Sensitivity Troponin T. J Am Coll Cardiol. 2018 Nov 6;72(19):2309–2320.
   PubMed Web of Science ®Google Scholar
• Pacho C, Domingo M, Nunez R, et al. Predictive biomarkers for death and rehospitalization in comorbid frail elderly heart failure patients. BMC Geriatr. 2018 May 9;18(1):109.
   PubMedGoogle Scholar
• Gaggin HK, Szymonifka J, Bhardwaj A, et al. Head-to-head comparison of serial soluble ST2, growth differentiation factor-15, and highly-sensitive troponin T measurements in patients with chronic heart failure. JACC Heart Fail. 2014 2;Feb(1):65–72.
   Google Scholar
• Wesseling M, Jhc DP, de Jager SCA. Growth differentiation factor 15 in adverse cardiac remodelling: from biomarker to causal player. ESC Heart Fail. 2020 Aug;7(4):1488–1501.
   PubMed Web of Science ®Google Scholar
• Fernandez ABM, Ferrero-Gregori A, Garcia-Osuna A, et al. Growth differentiation factor 15 as mortality predictor in heart failure patients with non-reduced ejection fraction. ESC Heart Fail. 2020 Oct;7(5):2223–2229.
   PubMed Web of Science ®Google Scholar
• Luo JW, Duan WH, Song L, et al. A Meta-Analysis of Growth Differentiation Factor-15 and Prognosis in Chronic Heart Failure. Front Cardiovasc Med.2021 Nov;5:8.
   Google Scholar
• de Boer RA, Yu L, van Veldhuisen DJ. Galectin-3 in cardiac remodeling and heart failure. Curr Heart Fail Rep. 2010 Mar;7(1):1–8.
   PubMedGoogle Scholar
• de Boer RA, Lok DJ, Jaarsma T, et al. Predictive value of plasma galectin-3 levels in heart failure with reduced and preserved ejection fraction. Ann Med. 2011 Feb;43(1):60–68.
   PubMed Web of Science ®Google Scholar
• Meijers WC, Januzzi JL, deFilippi C, et al. Elevated plasma galectin-3 is associated with near-term rehospitalization in heart failure: a pooled analysis of 3 clinical trials. Am Heart J. 2014 Jun;167(6):853–U117.
   PubMed Web of Science ®Google Scholar
• Wu C, Lv Z, Li X, et al. Galectin-3 in Predicting Mortality of Heart Failure: a Systematic Review and Meta-Analysis. Heart Surg Forum. 2021 Mar 30;24(2):E327–E332.
   PubMed Web of Science ®Google Scholar
• Barutaut M, Fournier P, Peacock WF, et al. sST2 adds to the prognostic value of Gal-3 and BNP in chronic heart failure. Acta Cardiol. 2020 Dec;75(8):739–747.
   PubMed Web of Science ®Google Scholar
• Damman K, Testani JM. The kidney in heart failure: an update. Eur Heart J. 2015 Jun 14;36(23):1437–+.
   PubMed Web of Science ®Google Scholar
• Smith GL, Lichtman JH, Bracken MB, et al. Renal impairment and outcomes in heart failure - Systematic review and meta-analysis. J Am Coll Cardiol. 2006 May 16;47(10):1987–1996.
   PubMed Web of Science ®Google Scholar
• Angelidis C, Deftereos S, Giannopoulos G, et al. Cystatin C: an Emerging Biomarker in Cardiovascular Disease. Curr Top Med Chem. 2013 Jan;13(2):164–179.
   PubMed Web of Science ®Google Scholar
• van der Laan SW, Fall T, Soumare A, et al. Cystatin C and Cardiovascular Disease A Mendelian Randomization Study. J Am Coll Cardiol. 2016 Aug 30;68(9):934–945.
   PubMed Web of Science ®Google Scholar
• Dupont M, Wu YP, Hazen SL, et al. Cystatin C Identifies Patients With Stable Chronic Heart Failure at Increased Risk for Adverse Cardiovascular Events. Circ-Heart Fail. 2012 Sep;5(5):602–609
   PubMed Web of Science ®Google Scholar
• Wang CH, Han S, Tong F, et al. Predictive Value of the Serum Cystatin C/Prealbumin Ratio in Combination With NT-proBNP Levels for Long-Term Prognosis in Chronic Heart Failure Patients: a Retrospective Cohort Study. Front Cardiovasc Med. Vol. 14. 2021 Jul; p. 8.
   Google Scholar
• Bayes-Genis A, Morant-Talamante N, Neprilysin LJ. Natriuretic Peptide Regulation in Heart Failure. Curr Heart Fail Rep. 2016 Aug;13(4):151–157.
   PubMedGoogle Scholar
• Bayes-Genis A, Barallat J, Galan A, et al. Soluble Neprilysin Is Predictive of Cardiovascular Death and Heart Failure Hospitalization in Heart Failure Patients. J Am Coll Cardiol. 2015 Feb 24;65(7):657–665.
   PubMed Web of Science ®Google Scholar
• Gommans DHF, Revuelta-Lopez E, Lupon J, et al. Soluble Neprilysin and Corin Concentrations in Relation to Clinical Outcome in Chronic Heart Failure. Jacc-Heart Fail. 2021 Feb;9(2):85–95
   PubMed Web of Science ®Google Scholar
• Damman K, van Veldhuisen DJ, Navis G, et al. Urinary neutrophil gelatinase associated lipocalin (NGAL), a marker of tubular damage, is increased in patients with chronic heart failure. Eur J Heart Fail. 2008;Oct;10(10):997–1000.
   PubMed Web of Science ®Google Scholar
• Villacorta H, Santos RA, Marroig MA, et al. Prognostic value of plasma neutrophil gelatinase-associated lipocalin in patients with heart failure. Rev Port Cardiol. 2015 Jul-Aug;34(7–8):473–478.
   PubMedGoogle Scholar
• Bolignano D, Basile G, Parisi P, et al. Increased plasma neutrophil gelatinase-associated lipocalin levels predict mortality in elderly patients with chronic heart failure. Rejuvenation Res. 2009 Feb;12(1):7–14.
   PubMed Web of Science ®Google Scholar
• Mann DL. The Emerging Role of Innate Immunity in the Heart and Vascular System For Whom the Cell Tolls. Circ Res. 2011 Apr 29;108(9):1133–U201.
   PubMed Web of Science ®Google Scholar
• Adamo L, Rocha-Resende C, Prabhu SD, et al. Reappraising the role of inflammation in heart failure. Nat Rev Cardiol. 2020 May;17(5):269–285.
   PubMed Web of Science ®Google Scholar
• Gowda SGB, Gowda D, Hou F, et al. Temporal lipid profiling in the progression from acute to chronic heart failure in mice and ischemic human hearts. Atherosclerosis. 2022;363:30–41.
   PubMed Web of Science ®Google Scholar
• Vizzardi E, Nodari S, D’Aloia A, et al. CA 125 tumoral marker plasma levels relate to systolic and diastolic ventricular function and to the clinical status of patients with chronic heart failure. Echocardiography. 2008 Oct;25(9):955–960.
   PubMed Web of Science ®Google Scholar
• D’Aloia A, Faggiano P, Aurigemma G, et al. Serum levels of carbohydrate antigen 125 in patients with chronic heart failure: relation to clinical severity, hemodynamic and Doppler echocardiographic abnormalities, and short-term prognosis. J Am Coll Cardiol. 2003 May 21;41(10):1805–1811.
   PubMed Web of Science ®Google Scholar
• Nagele H, Bahlo M, Klapdor R, et al. CA 125 and its relation to cardiac function. Am Heart J. 1999 Jun;137(6):1044–1049.
   PubMed Web of Science ®Google Scholar
• Anand IS, Latini R, Florea VG, et al. C-reactive protein in heart failure - Prognostic value and the effect of valsartan. Circulation. 2005 Sep 6;112(10):1428–1434.
   PubMed Web of Science ®Google Scholar
• Pellicori P, Zhang J, Cuthbert J, et al. High-sensitivity C-reactive protein in chronic heart failure: patient characteristics, phenotypes, and mode of death. Cardiovasc Res. 2020 Jan 1;116(1):91–100.
   PubMed Web of Science ®Google Scholar
• Traxler D, Zimmermann M, Simader E, et al. The inflammatory markers sST2, HSP27 and hsCRP as a prognostic biomarker panel in chronic heart failure patients. Clin Chim Acta. 2020;510:507–514.
   PubMed Web of Science ®Google Scholar
• Gonzalez GE, Rhaleb NE, D’Ambrosio MA, et al. Deletion of interleukin-6 prevents cardiac inflammation, fibrosis and dysfunction without affecting blood pressure in angiotensin II-high salt-induced hypertension. J Hypertens. 2015 Jan;33(1):144–152.
   PubMed Web of Science ®Google Scholar
• Fontes JA, Rose NR, Cihakova D. The varying faces of IL-6: from cardiac protection to cardiac failure. Cytokine. 2015 Jul;74(1):62–68.
   PubMed Web of Science ®Google Scholar
• Tsutamoto T, Hisanaga T, Wada A, et al. Interleukin-6 spillover in the peripheral circulation increases with the severity of heart failure, and the high plasma level of interleukin-6 is an important prognostic predictor in patients with congestive heart failure. J Am Coll Cardiol. 1998 Feb;31(2):391–398.
   PubMed Web of Science ®Google Scholar
• TorreAmione G, Kapadia S, Benedict C, et al. Proinflammatory cytokine levels in patients with depressed left ventricular ejection fraction: a report from the studies of left ventricular dysfunction (SOLVD). Journal of the American College of Cardiology. 1996 Apr;27(5):1201–1206.
   Google Scholar
• Kubota T, Miyagishima M, Alvarez RJ, et al. Expression of proinflammatory cytokines in the failing human heart: comparison of recent-onset and end-stage congestive heart failure. J Heart Lung Transpl. 2000 Sep;19(9):819–824.
   PubMed Web of Science ®Google Scholar
• MacGowan GA, Mann DL, Kormos RL, et al. Circulating interleukin-6 in severe heart failure. Am J Cardiol. 1997 Apr 15;79(8):1128.
   PubMed Web of Science ®Google Scholar
• Gwechenberger M, Hulsmann M, Berger R, et al. Interleukin-6 and B-type natriuretic peptide are independent predictors for worsening of heart failure in patients with progressive congestive heart failure. J Heart Lung Transpl. 2004 Jul;23(7):839–844.
   PubMed Web of Science ®Google Scholar
• Held C, White HD, Stewart RAH, et al. Inflammatory Biomarkers Interleukin-6 and C-Reactive Protein and Outcomes in Stable Coronary Heart Disease: experiences From the STABILITY (Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy) Trial. J Am Heart Assoc. 2017;6(10):Oct.
   Web of Science ®Google Scholar
• Chia YC, Kieneker LM, van Hassel G, et al. Interleukin 6 and Development of Heart Failure With Preserved Ejection Fraction in the General Population. J Am Heart Assoc. 2021;10:11.
   Web of Science ®Google Scholar
• Markousis-Mavrogenis G, Tromp J, Ouwerkerk W, et al. The clinical significance of interleukin-6 in heart failure: results from the BIOSTAT-CHF study. Eur J Heart Fail. 2019 Aug;21(8):965–973.
   PubMed Web of Science ®Google Scholar
• Eidizadeh A, Schnelle M, Leha A, et al. Biomarker profiles in heart failure with preserved vs. reduced ejection fraction: results from the DIAST-CHF study. ESC Heart Fail. 2022 Oct 2;10(1).
   PubMedGoogle Scholar
• van der Pol A, van Gilst WH, Voors AA, et al. Treating oxidative stress in heart failure: past, present and future. Eur J Heart Fail. 2019 Apr;21(4):425–435.
   PubMed Web of Science ®Google Scholar
• Frangogiannis NG. The Extracellular Matrix in Ischemic and Nonischemic Heart Failure. Circ Res. 2019 Jun 21;125(1):117–146.
   PubMed Web of Science ®Google Scholar
• Myeloperoxidase NG. - A bridge linking inflammation and oxidative stress with cardiovascular disease. Clin Chim Acta. 2019 Jun;493:36–51.
   PubMed Web of Science ®Google Scholar
• Tang WHW, Tong W, Troughton RW, et al. Prognostic value and echocardiographic determinants of plasma myeloperoxidase levels in chronic heart failure. J Am Coll Cardiol. 2007 Jun 19;49(24):2364–2370.
   PubMed Web of Science ®Google Scholar
• Tang WHW, Brennan ML, Philip K, et al. Plasma myeloperoxidase levels in patients with chronic heart failure. Am J Cardiol. 2006 Sep 15;98(6):796–799.
   PubMed Web of Science ®Google Scholar
• Bouwens E, Schuurman AS, Akkerhuis KM, et al. Associations of serially measured PCSK9, LDLR and MPO with clinical outcome in heart failure. Biomark Med. 2021 Jan;15(4):247–255.
   PubMed Web of Science ®Google Scholar
• Avaliani T, Talakvadze T, Tabagari S. Prognostic Value of Plasma Myeloperoxidase Level’s and Echocardiographic Determinants in Chronic Heart Failure Patients. Georgian Med News. 2019 Mar;288:55–60.
   Google Scholar
• Tang WH, Shrestha K, Troughton RW, et al. Integrating plasma high-sensitivity C-reactive protein and myeloperoxidase for risk prediction in chronic systolic heart failure. Congest Heart Fail. 2011 May-Jun;17(3):105–109.
   PubMedGoogle Scholar
• Deardorff R, Spinale FG. Cytokines and matrix metalloproteinases as potential biomarkers in chronic heart failure. Biomark Med. 2009 Oct;3(5):513–523.
   PubMed Web of Science ®Google Scholar
• Jordan A, Roldan V, Garcia M, et al. Matrix metalloproteinase-1 and its inhibitor, TIMP-1, in systolic heart failure: relation to functional data and prognosis. J Intern Med. 2007 Sep;262(3):385–392.
   PubMed Web of Science ®Google Scholar
• George J, Patal S, Wexler D, et al. Circulating matrix metalloproteinase-2 but not matrix metalloproteinase-3, matrix metalloproteinase-9, or tissue inhibitor of metalloproteinase-1 predicts outcome in patients with congestive heart failure. Am Heart J. 2005 Sep;150(3):484–487.
   PubMed Web of Science ®Google Scholar
• Chang YY, Chen AR, Wu XM, et al. Comparison the Prognostic Value of Galectin-3 and Serum Markers of Cardiac Extracellular Matrix Turnover in Patients with Chronic Systolic Heart Failure. Int J Med Sci. 2014;11(11):1098–1106.
   PubMed Web of Science ®Google Scholar
• Liu Y, Wang X, Pan X, et al. Prognostic value of plasma sAXL in patients with heart failure: insights from the DRAGON-HF trial. ESC Heart Fail. 2022 Nov; p. 27.
   Google Scholar
• Rincon LM, Rodriguez-Serrano M, Conde E, et al. Serum microRNAs are key predictors of long-term heart failure and cardiovascular death after myocardial infarction. ESC Heart Fail. 2022 Oct;9(5):3367–3379.
   PubMed Web of Science ®Google Scholar
• Roy C, Lejeune S, Slimani A, et al. Fibroblast growth factor 23: a biomarker of fibrosis and prognosis in heart failure with preserved ejection fraction. ESC Heart Fail. 2020 Oct;7(5):2494–2507.
   PubMed Web of Science ®Google Scholar
• van Boven N, Battes LC, Akkerhuis KM, et al. Toward personalized risk assessment in patients with chronic heart failure: detailed temporal patterns of NT-proBNP, troponin T, and CRP in the Bio-SHiFT study. Am Heart J. 2018 Feb;196:36–48.
   PubMed Web of Science ®Google Scholar
• Gurgoze MT, van Vark LC, Baart SJ, et al. Multimarker Analysis of Serially Measured GDF-15, NT-proBNP, ST2, GAL-3, cTnI, Creatinine, and Prognosis in Acute Heart Failure. Circ Heart Fail. 2022 Nov 21;16(1):e009526.
   PubMedGoogle Scholar
• Maisel A, Januzzi J, Xue Y, et al. Post-acute care: the role of natriuretic peptides. Congest Heart Fail. 2012;Sep-Oct;18(Suppl 1):S14–6.
   Google Scholar
• Felker GM, Hasselblad V, Hernandez AF, et al. Biomarker-guided therapy in chronic heart failure: a meta-analysis of randomized controlled trials. Am Heart J. 2009 Sep;158(3):422–430.
   PubMed Web of Science ®Google Scholar
• Troughton RW, Frampton CM, Brunner-La Rocca HP, et al. Effect of B-type natriuretic peptide-guided treatment of chronic heart failure on total mortality and hospitalization: an individual patient meta-analysis. Eur Heart J. 2014 Jun 14;35(23):1559–1567.
   PubMed Web of Science ®Google Scholar
• Savarese G, Trimarco B, Dellegrottaglie S, et al. Natriuretic peptide-guided therapy in chronic heart failure: a meta-analysis of 2,686 patients in 12 randomized trials. PLoS One. 2013;8(3):e58287.
   PubMed Web of Science ®Google Scholar
• Shirakabe A, Okazaki H, Matsushita M, et al. Type III procollagen peptide level can indicate liver dysfunction associated with volume overload in acute heart failure. ESC Heart Fail. 2022 Jun;9(3):1832–1843.
   PubMed Web of Science ®Google Scholar
• Boorsma EM, JM TM, Damman K, et al. Congestion in heart failure: a contemporary look at physiology, diagnosis and treatment. Nature Reviews Cardiology. 2020 Oct;17(10):641–655
   PubMed Web of Science ®Google Scholar
• Egerstedt A, Czuba T, Bronton K, et al. Bioactive adrenomedullin for assessment of venous congestion in heart failure. ESC Heart Fail. 2022 Oct;9(5):3543–3555.
   PubMed Web of Science ®Google Scholar
• Nunez J, De la Espriella R, Rossignol P, et al. Congestion in heart failure: a circulating biomarker-based perspective. A review from the Biomarkers Working Group of the Heart Failure Association, European Society of Cardiology. Euro J Heart Fail. 2022 Sep 7;24(10).
   Web of Science ®Google Scholar